Entacapone is an antiparkinsonian drug which block L-dopa metabolism, inhibiting the C-O-methyltransferase (COMT) enzyme. There is an individual variability of the COMT activity determined by a genetic polymorphism. The aim of this study is to investigate whether the genetic variability influences entacapone efficacy in Parkinson's disease.
COMT protein is dependent of a single autosomal locus with two co-dominant alleles with a high activity (allele H) and a low activity (allele L) form of the enzyme. L and H allele frequency in the Caucasian population is around 50%. This is a monocentric randomized blinded cross-over study comparing acute challenge of L-dopa + placebo versus L-dopa + 200 mg entacapone, in Parkinson's disease patients with HH and LL genotypes.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
60
entacapone
l dopa versus placebo
Centre d'Investigation Clinique, Hôpital de la Pitié-Salpétrière,
Paris, France
L-dopa efficacy duration on UPDRS motor scale during an acute L-dopa test
L-dopa efficacy duration on UPDRS motor scale during an acute L-dopa test
Time frame: during the hospitalization in 24 hours
Pharmacokinetics of L-dopa and its metabolites
Pharmacokinetics of L-dopa and its metabolites
Time frame: at the end of the study during the last hospitalization
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.